Pharmacia & Upjohn Vestra
Executive Summary
P&U anticipates a spring launch of the norepinephrine reuptake inhibitor. The company's most-recent submission to the agency was in August, suggesting that the user fee deadline may be in late February. The original submission was based solely on non-U.S. patients. In an article on pending NDAs, "The Pink Sheet" (Jan. 10, p. 5) misidentified the class of the antidepressant